Drug Profile
Research programme: anticancer therapeutics - Valerio Therapeutics/Royal College of Surgeons in Ireland Valerio Therapeutics
Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator Onxeo SA
- Developer Valerio Therapeutics
- Class Antineoplastics
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in France
- 07 Jul 2016 Onxeo and the Royal College of Surgeons in Ireland enter into a collaboration to develop new compounds derived from belinostat
- 07 Jul 2016 Early research in Cancer in France (unspecified route)